Introduction: Poorly differentiated, G3 NECs are associated with poor outcomes and have no effective treatment options apart from cytotoxic chemotherapy.
Aim(s): To investigate the efficacy of Avelumab, an anti-PD-L1 monoclonal antibody, in poorly differentiated, G3 NECs.
Materials and methods: The NET001 study (NCT03278405) is a single center, phase IIA study of Avelumab, (10mg/kg/IV every 2 weeks for a period of 52 weeks) in pts with poorly differentiated, WHO 2010 G3 NECs, from a gastrointestinal (GI) or lung source, who have progressed on a maximum of 2 lines of prior therapy.. The primary endpoint was ORR by RECIST v1.1; secondary endpoints included mPFS, mOS, DCR at 6 months, and toxicity.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Victor Rodriguez-Freixinos
, Chan D
, Doherty M
, Wasson K
, Iscoe N
, Raskin W
, Hallet J
, Myrehaug S
, Law C
, Thawer A
, Nguyen K
, Singh S
To read results and conclusion, please login ...
Further abstracts you may be interested in